The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Earnings-manipulation signal · Beneish M -5.08 — no flag raisedOK
- Earnings quality 79/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as SANGAMO THERAPEUTICS, INC reports it. History and quarterly detail are in the app.
- License$18.0M
- Initial License$7.6M
Leadership changes
From SANGAMO THERAPEUTICS, INC's own filings, the day they're filed.
- Prathyusha Duraibabu · Chief Financial Officer · departureeff. 2025-10-01
- Nikunj Jain · principal accounting officer · appointmenteff. 2025-09-24
- Chartered Accountant · directors · appointment
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SANGAMO THERAPEUTICS, INC, every answer cited to the official filings🔒
- The Intelligence Brief — added when SANGAMO THERAPEUTICS, INC's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.